Scientific Advisory Board
Hillel Bachrach, Chairman, Viztek & UltraSPECT
James Barry, Ph.D., Executive Vice President & Chief Operating Officer, InspireMD, Inc.
Kevin J. Bitterman, Ph.D., Principal, Polaris Venture Partners
Dalia Cohen, Ph.D., Head of Research, Beryllium
James J. Collins, Ph.D., Professor of Biomedical Engineering & Science, Massachusetts Institute of Technology
John M. Collins, Ph.D., Chief Operating Officer, Center for Integration of Medicine & Innovative Technology (CIMIT)
T. (Teo) Forcht Dagi, M.D., Chairman, CV6 and healthEgames
Robert D’Amato, M.D., Ph.D., Judah Folkman Chair in Surgery, and Director, Center for Macular Degeneration Research, Children’s Hospital Boston
Glenn R. Gaudette, Ph.D., Associate Professor, Biomedical Engineering, Worcester Polytechnic Institute
José-Carlos Gutiérrez-Ramos, Ph.D., President and Chief Executive Officer, Synlogic, Inc
Andrew Jay, DMD, Fund Head, Healthcare Fund, Siemens Venture Capital
Rick Jones, MD, Co-COO, Broadview Ventures
Henry Kay, U.S. Partner, Medica Venture Partners
Dale Larson, Director of Biomedical Systems, Draper Laboratory
Judith Lieberman, Ph.D., M.D., Senior Investigator, Immune Disease Institute, Children’s Hospital Boston and Professor of Pediatrics, Harvard Medical School
Lita L. Nelsen, Former Director, Technology Licensing Office, Massachusetts Institute of Technology
Barbara Osborne Ph.D., Professor of Veterinary and Animal Sciences, University of Massachusetts Amherst
Carmichael Roberts, Ph.D., Partner, North Bridge Venture Partners
Frederick J. Schoen, M.D., Ph.D., Executive Vice-Chairman, Department of Pathology at Brigham and Women’s Hospital
Lauren Silverman, Ph.D., Managing Director, Novartis Option Fund
Alison Taunton-Rigby, Ph.D., Co-Founder, Chief Executive Officer and Director, RiboNovix, Inc.
Guillermo Tearney, M.D., Ph.D., Professor of Pathology, Harvard Medical School
David Walt, Ph.D., Robinson Professor of Chemistry, and Howard Hughes Medical Institute Professor, Tufts University
Hillel Bachrach joins the Scientific Advisory Board with over 30 years of hands-on experience as an entrepreneur, as well as great success in innovative medical technologies. Bachrach is the managing partner of 20/20 HealthCare Partners LLC. Previous work includes co-founding ESC Medical, (now Lumenis), Msq, (now Alma Lasers) and Orex Computed Radiography. He is now the active Chairman of Viztek & UltraSPECT and on the BOD of: Corindus, SRS as well as other healthcare and hi-tech companies also funded by 20/20 HealthCare Partners.
James J. Barry, Ph.D., is executive vice president and chief operating officer of InspireMD, Inc. Prior to Arsenal Medical, Dr. Barry held a variety of senior positions at Boston Scientific, most recently senior vice president of Corporate Technology Development where he oversaw corporate R&D and preclinical science. While at Boston Scientific, Dr. Barry initiated and led the company’s drug-eluting stent programs. Under Dr. Barry’s leadership, the TAXUS™ drug-eluting coronary stent was developed and became the most successful medical device ever launched, attaining annual sales exceeding $3 billion. Prior to joining Boston Scientific, Dr. Barry held positions at Howmedica and Kontron Instruments. Dr. Barry is the author of multiple articles in peer reviewed publications and holds more than 35 U.S. patents.
He currently serves on the advisory boards of the University of Massachusetts-Lowell College of Sciences and Yale University’s College of Biomedical Engineering. Dr. Barry holds a doctorate in biochemistry from the University of Massachusetts-Lowell and a Bachelor of Arts in chemistry from Saint Anselm College.
Kevin is a Partner at Polaris Partners. He joined Polaris in 2004 and focuses on investments in healthcare. Prior to joining Polaris, Kevin completed his PhD in genetics at Harvard Medical School. He is a cofounder of Genocea Biosciences (NASDAQ: GNCA) and Sirtris Pharmaceuticals (GSK) and was the founding CEO at Visterra Inc. and Editas Medicine.
Kevin currently represents Polaris as a Director of Editas Medicine, InSeal Medical, Genocea Biosciences, Kala Pharmaceuticals, Neuronetics, Inc., Visterra Inc., Taris Biomedical, and Vets First Choice.
Dr. Cohen is Chief Scientific Officer at Asterand, Inc. and worked for many years at Novartis where, among other positions, she was Vice President-Global Head of Functional Genomics, Novartis Institute for Biomedical Research. She also served as Chief Scientific Officer at Rosetta Genomics. Cohen received her B.Sc. In Biology, M.Sc. in Virology and Ph.D. in Cell Biology from the Technion, Israel Institution of Technology and completed her postdoctoral at Albert Einstein College of Medicine.
James J. Collins is a Professor of Biomedical Engineering at Boston University. He is one of the founders of the emerging field of synthetic biology, and a pioneering researcher in systems biology, stochastic resonance, biological dynamics and neurostimulation. Collins has invented a number of novel devices and techniques, including vibrating insoles for enhancing balance, bistable genetic toggle switches for biotechnology and bioenergy applications, and systems biology techniques for identifying drug targets and disease mediators.
Dr. Collins has co-founded two companies based on his technologies: Afferent Corporation, a medical device company, and Cellicon Biotechnologies, a drug discovery company. Dr. Collins is also a member of the Scientific Advisory Board (SAB) of Codon Devices, Inc., and has served on the SAB of Mannkind Corporation (Nasdaq: MNKD) and Bios Group Inc.
Collins’ has received numerous awards including the 2007 NIH Director’s Pioneer Award and the Ellison Medical Foundation Senior Scholar Award in Aging. From 1987 to 1990, he was a Rhodes Scholar, since which he has been a faculty member in the Department of Biomedical Engineering at Boston University and currently serves as Co-Director of the Center for BioDynamics at Boston University, in addition to performing his duties as a professor.
John M. Collins, PhD, is the COO of CIMIT – Consortia for Improving Medicine with Innovation and Technology. Before coming to CIMIT, he was president of TIAX LLC, the technology processing company. He has more than 25 years of hands-on, international experience operating at the junction of technology and business, accelerating the development of new technologies and commercialization of innovative products and services, including several years as president of TIAX LLC. Dr. Collins received his BS in mechanical engineering from Rensselaer Polytechnic Institute and his MS and PhD in mechanical engineering from MIT with a concentration in bio-fluids, fluid mechanics and heat/mass transfer. He holds more than 20 US patents on new products and manufacturing processes, including trocars and staplers for MIS, blood fluid warmers, and tendon and ligament repair methods.
T (Teo) Forcht Dagi received an AB from Columbia College, an MD and MPH from Johns Hopkins, an MTS from Harvard, where he was a Joseph P. Kennedy, Jr. Fellow, an MBA with distinction from the Wharton School, and a DMedSc from Queen’s University Belfast. He trained in neurosurgery at the Massachusetts General Hospital and in London. He is a diplomat of the American Board of Neurological Surgeons, an elected Fellow of the College of Critical Care Medicine, and was bestowed fellowship ad hominem by the Royal College of Surgeons in Edinburgh.
Teo’s scientific interests have focused on brain monitoring and imaging, as well as neuro-oncology, head injury, stroke and translational surgery. He has also worked in the areas of telemedicine and patient safety. He holds faculty appointments at Queen’s University Belfast, the Center for Biomedical Ethics at Harvard Medical School, and the University of Prince Edward Island.
Teo has been involved in health care and life sciences venture capital for two decades, and has served as a director of public and private companies, and of several not-for-profit organizations. He is currently Chairman of CV6 Technologies and healthEgames, and a director of Axela Biosensors, Vittamed and ViaImmune. He was in the past Director of the Wharton School and the Georgia Institute of Technology. Currently, holds appointments as an Overseer of the Beth Israel Deaconess Medical Center, Vice-Chair of the Council on Surgical and Perioperative Safety, and Director of the Anesthesia Patient Safety Foundation. He lectures widely on innovation and invention in medicine. He is an Advisor to Broadview Ventures and a Managing Partner of the Salutramed Group. He serves as an editor of Neurosurgery and the Journal of Clinical Ethics.
Robert D’Amato received his B.A, M.D. and Ph.D. from Johns Hopkins University. He completed his Ophthalmology residency at the Massachusetts Eye and Ear Infirmary. After this training, he undertook a postdoctoral research fellowship in the Folkman laboratories. He has been an independent investigator at Children’s since 1994 and is a Professor of Ophthalmology at Harvard Medical School. He currently holds the Judah Folkman Chair in Surgery and leads the endowed Karp Laboratory for Macular Degeneration Research.
Noteworthy past research includes the discovery that thalidomide and analogs are angiogenesis inhibitors, which are now FDA approved for cancer. Additional his lab discovered a major role of genetics in determining an individual’s angiogenic responsiveness.
Glenn R. Gaudette, Ph.D., is an Associate Professor of Biomedical Engineering at Worcester Polytechnic Institute. His research aims to develop a treatment for the millions of Americans suffering from myocardial infarction and other cardiovascular diseases. He is focused on regenerating mechanical and electrophysiological function in the heart. Dr. Gaudette has over 20 years experience in the cardiac research field, including over 10 years in cardiac surgery research. He has over 50 peer reviewed publications, several book chapters and recently edited a book on cardiac regeneration. In May of 2012, he co-founded a company based on some of the pioneering technology developed in his laboratory. Dr. Gaudette won the 2012 Massachusetts Life Science Innovation Day competition and his work has been featured in many different media outlets. He currently teaches biomedical engineering design, biomechanics and physiology. His research has been supported by government (National Institutes of Health; National Science Foundation), non-profit (American Heart Association) and industrial partners.
Dr. Gutiérrez-Ramos joined Synlogic from Pfizer where he served as Group Senior Vice President and global head of the BioTherapeutics Research. In that role, he held responsibility for more than 25 novel programs across the full spectrum of clinical development, re-launched efforts in Rare Disease Discovery and Development and founded the Centers for Therapeutic Innovation. Before joining Pfizer Dr. Gutiérrez-Ramos was Senior Vice President and Head of the Immuno-Inflammation Centre of Excellence for Drug Discovery at GlaxoSmithKline. He has also served as Senior Vice President of Research and Non-Clinical Development and Chief Scientific Officer at Avidia and was a Senior Scientist and Head of Experimental Therapeutics at Millenium Pharmaceuticals. Dr. Gutiérrez-Ramos has PhD’s from both the Basel Institute for Immunology and by the Autonoma University of Madrid, Spain.
Andrew has sat on the boards of several portfolio companies and he currently oversees the investments in ViewRay and Aventura. Previously, he has been involved with U-Systems, MDdatacor, Zonare, Lifemasters and Sequenom. Outside the portfolio he serves on the Board of Billerica based Belmont Instruments. Prior to joining Siemens, Andrew was an I. I. ranked analyst following the medical technology industry at Alex Brown and Wachovia Securities. Sectors under coverage included neurologic devices, imaging, orthopedics, cardiovascular, vision, and diabetes, where he brought numerous companies public, and published over 10,000 pages of research. Dr. Jay’s prior experience includes leading consulting projects for Arthur D. Little and running his substantial dental practice. He has a Bachelor of Science from Rensselaer Polytechnic Institute, a DMD from the University of Pennsylvania and an MBA from the Kellogg School at Northwestern. Outside of the office Andrew was part of the founding team at the Massachusetts Oyster Project, which is working to restore oysters to the estuaries around the Commonwealth. (http://www.massoyster.org)
Frederick “Rick” Jones, MD, shares responsibility for the day-to-day operations of Broadview Ventures, including identification and screening of new opportunities, due diligence, negotiation of deal structure, and portfolio company board involvement. Prior to joining Broadview Ventures, Rick founded Spordiff Therapeutics, which is developing a small molecule to prevent C. difficile infection. Previously, Rick was CEO of Anchor Therapeutics, a venture-backed company developing a platform of lipidated peptides targeting intractable GPCR targets. Before that Rick held increasingly responsible positions as a general manager, business development professional and medical affairs officer with Devgen, BioRexis and Wyeth Pharmaceuticals. Early in his career, Dr. Jones practiced internal medicine, most recently as Assistant Professor in the University of Pennsylvania health system. Rick earned his undergraduate, medical and MBA degrees from the University of Pennsylvania.
Henry Kay is an active member of two Angel Investing Groups (Boston Harbor Angels and Launchpad) and is the U.S. Partner of Medica Venture Partners, a healthcare dedicated VC based in Israel. He retired from Boston Scientific in 2006, where he was Group Vice President of New Market Development / Strategic Planning, Endosurgery Boston Scientific Corporation (BSC). He has 40 years of experience in the medical industry in roles which include R&D, International Marketing, Regulatory Affairs, and Strategic Planning for major pharmaceutical companies, including Schering-Plough, American Home Products, Sterling Drug and Allergan.
Henry is a fellow of the Royal Society of Medicine (UK). He serves on the Boards of several start up health care companies, including Smart Cells (sold to Merck in 2010), Cool Systems, Avaxia, Cristcot Medical and Cannuflow. He was a member of the board of Directors of Microfluidics, a public company in the equipment space for pharmaceutical manufacture (sold to IDEX in 2010) Internationally, he serves on the boards of 3 Canadian Medical Device companies (Cellaegis Devices and Imagistx in Toronto; Prev Biotech in Edmonton and Dartmouth Medical Research laboratories, Halifax). He has been a mentor with the Venture Mentoring Service of MIT. He serves on the Board of Overseers of Beth Israel-Deaconess and Newton Wellesley Hospitals. In addition, he is serving on the boards of Neurofibromatosis (NF Inc.) and JF&CS, all non-profit organizations.
Dale Larson is responsible for setting the research agenda and conducts his own work in the area of Nanohole array sensing and laboratory automation. Before joining Draper in February of 2008 Dale was the founding Director of the Technology and Engineering Center at Harvard Medical School where the Nanohole array sensing and automation work was initiated. He has over 30 years of experience in the development of analytical and clinical instrumentation in both academia and in industry. He is an industry veteran of the medical diagnostics industry and was also the President and COO of Genomics Collaborative following a lengthy medical product development consulting career at Arthur D. Little. Mr. Larson received his B.S. from the University of Virginia in 1980 and his M.S. from Stanford University in 1981.
Children’s Hospital Boston and Professor of Pediatrics, Harvard Medical School Judy Lieberman is Chair in Cellular and Molecular Medicine in the Program in Cellular and Molecular Medicine at Boston Children’s Hospital and Professor of Pediatrics at Harvard Medical School. She earned a Ph.D. in physics from Rockefeller University and was a physicist at the Institute for Advanced Study in Princeton before earning an M.D. from Harvard and MIT. Dr. Lieberman trained in internal medicine and hematology-oncology at Tufts Medical Center and was a postdoctoral fellow in immunology at MIT. She does research on how cytotoxic T cells destroy cells marked for immune elimination, HIV immunology, and how microRNAs regulate cell differentiation and cancer. She was the first to show that RNA interference could be harnessed to treat disease in an animal and is actively developing RNAi-based therapeutics for viral infection and cancer. She is a member of the American Academy of Arts and Sciences.
Lita Nelsen is the Director of the Technology Licensing Office at the Massachusetts Institute of Technology, where she has been since 1986. She began her tenure at the MIT TLO specializing in biotechnology and has helped begin many of the biotechnology companies in Massachusetts. Previously, Ms. Nelsen spent 20 years in industry at such companies as Amicon, Millipore, Arthur D. Little, Inc., and Applied Biotechnology. Nelsen currently serves on the Board of the Massachusetts Technology Development Corporation and the Mount Auburn Hospital. She is a founder of Praxis, Ltd., a non-profit company for training technology transfer professionals, for which she was awarded an MBE. She is a former president of the Association of University Technology and is an advisor to a number of international organizations concerned with the intellectual property and the development of medicines for neglected tropical diseases.
Since coming to UMass Amherst in 1985, Professor of Veterinary and Animal Sciences Barbara Osborne, a renowned immunologist, has followed her research through a number of twists and turns. In the 19990s, Dr. Osborne earned international renown as a researcher of apoptosis, or programmed cell death. Hematech, a start-up Dr. Osborne co-founded in 1999, pioneered the use of cloned animals for the development and production of antibodies for therapeutic uses. Now, with support from a 2011 UMass President’s Science and Technology Initiatives Fund, Dr. Osborne is working with Grew Tew and Maria Santore of the Department of Polymer Science and Engineering to open the groundbreaking Center for Soft Materials Immunology, where UMass faculty and collaborators are developing biologically compatible synthetic materials that allow the body’s own cellular mechanisms and pathways to control the immune system in order to fight disease. Dr. Osborne holds a Ph.D. from Stanford University and performed postdoctoral training at the National Institutes of Health. She has also co-authored Immunology, a leading textbook in the subject.
Dr. Carmichael Roberts is a Partner of North Bridge Venture Partners. He received his B.S. and Ph.D. in organic chemistry from Duke University and completed his postdoctoral National Science Foundation fellowship at Harvard University. Dr. Roberts also has an MBA from the MIT Sloan School of Management. He serves as an advisor for MIT’s Deshpande Center for Technological Innovation, Harvard’s Nanoscale Science and Engineering Center, and schools of Science and Engineering at Duke University.
Frederick J. Schoen, M.D., Ph.D., is a Professor of Pathology and Health Sciences and Technology at Harvard Medical School. He is also the Executive Vice-Chairman for the Department of Pathology at Brigham and Women’s Hospital (BWH) and the Director of the BWH Biomedical Research Institute Technology Innovation Program. Schoen has extensive experience in preclinical and clinical development and evaluation of heart valve substitutes and other medical devices, translational innovation, and academic-corporate collaboration.
Dr. Lauren Silverman is a Managing Director of the Novartis Option Fund in Cambridge, MA, USA. Prior to joining the Option Fund she was Global Head of Oncology Research Operations for Novartis. Previously, Dr. Silverman spent much of her career in Licensing & Business Development, first at OSI Pharmaceuticals and later at Pfizer with responsibilities in the areas of CNS, ophthalmology and oncology. Dr. Silverman was also a Director of Strategic Alliances and Head of Cell Biology where she led multiple research teams after having been a founding scientist of Cadus Pharmaceuticals. She was a postdoctoral fellow at Memorial Sloan Kettering Cancer Center and Princeton University and earned her Ph.D. in molecular biology from the University of Utah.
She serves on the Business Advisory Board of the Epilepsy Research Foundation’s Epilepsy Therapy Project, National Cancer Institute’s SBIR review panel, Massachusetts Life Sciences Center’s Scientific Advisory Board and Board of Directors of Science Club for Girls. Dr. Silverman currently serves on the Boards of Directors of the Novartis Venture Funds portfolio companies: Anchor Therapeutics, Ra Pharmaceuticals, Inc., Proteostasis Therapeutics, Pulmatrix Inc., Viamet Pharmaceuticals, Inc., and Celladon Corporation.
Dr. Alison Taunton-Rigby has more than 30 years of experience in the biomedical and pharmaceutical sectors. As an industry leader in the life science and healthcare sectors she has achieved results in developing products and building companies. Dr. Taunton-Rigby has managed product development from basic research to FDA approval, marketing and sales. Her experience includes: significant strategic, regulatory, sales, reimbursment and international experience. She was awarded the OBE (Officer of the Order of the British Empire) in June 2002 by Her Majesty, Queen Elizabeth II for leadership in the research, development and promotion of biotechnology.
Guillermo Tearney M.D., Ph.D., is Professor of Pathology at Harvard Medical School, an Affiliated Faculty member of the Harvard-MIT Division of Health Sciences and Technology (HST), and the Associate Director of the Wellman Center for Photomedicine at the Massachusetts General Hospital. Dr. Tearney received his MD magna cum laude from Harvard Medical School and received his PhD in Electrical Engineering and Computer Science from the Massachusetts Institute of Technology.
Dr. Tearney’s research interests are focused on the development and clinical validation of non-invasive, high-resolution optical imaging methods for disease diagnosis. Dr. Tearney’s lab was the first to perform human imaging in the coronary arteries and gastrointestinal tract in vivo with Optical Coherence Tomography (OCT). Dr. Tearney has also developed several other technologies, including a confocal endomicroscope capable of imaging the entire esophagus, an ultraminiature three-dimensional endoscope, a highly efficient form of near field scanning optical microscopy (NSOM), and novel fluorescence spectroscopy and multimodality imaging techniques. Dr. Tearney is co-editor of The Handbook of Optical Coherence Tomography and has written over 170 peer-reviewed publications, including papers that have been highlighted on the covers of Science, Nature Medicine, Circulation, Gastroenterology, and Journal of American College of Cardiology.
Dr. Tearney’s work extends beyond his laboratory at MGH, many of his technologies are being produced commercially and he has founded the International Working Group on Intracoronary OCT Standardization and Validation, a group that is dedicated to establishing standards to ensure the widespread adoption of this imaging technology.
Dr. David Walt is Robinson Professor of Chemistry, and Howard Hughes Medical Institute Professor at Tufts University. He is a Member of the National Academy of Engineering, a Fellow of the American Institute of Medical and Biological Engineers, a Fellow of the American Association for the Advancement of Science, and is a Panel Member of the Bill and Melinda Gates Foundation’s Global Health Diagnostics Working Group. Dr. Walt has published over 200 papers and is named as an inventor or co-inventor of over 40 patents. He also serves as a board member for Quanterix, Inc. Dr. Walt holds a B.S. in Chemistry from the University of Michigan and received his Ph.D. in Chemical Biology from SUNY at Stony Brook.